New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 18, 2012
07:02 EDTARWRArrowHead Research signs agreement with Shire AG
Arrowhead Research announced that it has signed a research collaboration and license agreement with Shire AG, to develop and commercialize targeted peptide-drug conjugates by utilizing Arrowhead's human-derived Homing Peptide platform and Shire's therapeutic payloads. Arrowhead will receive research funding and could be eligible for development, regulatory, and commercialization milestone payments of up to $32.8M for each development candidate, plus additional milestone payments for a second indication, and royalties on worldwide sales. Additional financial terms of the agreement were not disclosed.
News For ARWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 18, 2015
10:37 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP ZIOP CLNE ARIA VHC AOL KING XON PEIX
May 15, 2015
10:20 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP RAX KING AOL WPZ RL Z MBI
May 14, 2015
10:56 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
May 13, 2015
11:08 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
May 12, 2015
10:16 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: NDLS WTW FUEL AOL LC NLNK ZU CYBR ARWR HZNP
May 11, 2015
16:09 EDTARWRArrowhead reports Q2 EPS (51c), consensus (34c)
Reports Q2 revenue $43,750, consensus $110,000.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use